BRAF和RAS突变对FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐珠单抗一线治疗疗效的影响:FIRE-3(AIO KRK-0306)研究分析
该研究回顾性检测FIRE-3试验中患者的BRAF和RAS突变,分析其对FOLFIRI联合西妥昔单抗或贝伐珠单抗一线治疗疗效的影响。在BRAF突变患者中,西妥昔单抗组客观缓解率数值上高于贝伐珠单抗组(52%对40%),但无进展生存期和总生存期无显著差异。在RAS突变患者中,西妥昔单抗组相比贝伐珠单抗组客观缓解率有降低趋势(37%对50.5%,P=0.11),无进展生存期有缩短趋势(7.4对9.7个月;HR 1.25;P=0.14),总生存期无显著差异。早期肿瘤退缩与西妥昔单抗获益相关。
要点
- 在BRAF突变患者中,西妥昔单抗组客观缓解率数值上高于贝伐珠单抗组(52%对40%),但生存期无显著差异。
- 在RAS突变患者中,西妥昔单抗组相比贝伐珠单抗组客观缓解率有降低趋势(37%对50.5%,P=0.11),无进展生存期有缩短趋势(7.4对9.7个月;HR 1.25;P=0.14)。
- 早期肿瘤退缩与西妥昔单抗治疗的获益相关,而与贝伐珠单抗治疗的获益无关。
核心结论
- 在BRAF突变和RAS突变患者中,基于西妥昔单抗和基于贝伐珠单抗的治疗具有相似的生存期。
- 早期肿瘤退缩是与抗EGFR治疗获益相关的早期参数,而在VEGF-A阻断治疗中未见此关联。
研究设计与样本
- 对FIRE-3试验中接受治疗的患者进行回顾性检测,使用福尔马林固定石蜡包埋肿瘤组织,通过焦磷酸测序检测KRAS和NRAS外显子2、3、4突变以及BRAF突变。
- 生存分析采用Kaplan-Meier法,组间差异用log-rank检验;客观缓解率比较采用Fisher精确检验;使用中心独立影像学缓解评估数据计算早期肿瘤退缩和缓解深度。
主要发现
- 共识别出188例RAS突变肿瘤患者和48例BRAF突变肿瘤患者。
- 在BRAF突变患者中,西妥昔单抗组与贝伐珠单抗组相比:客观缓解率数值上较高(52%对40%),无进展生存期风险比HR=0.84(P=0.56),总生存期HR=0.79(P=0.45)。
- 在RAS突变患者中,西妥昔单抗组与贝伐珠单抗组相比:客观缓解率有降低趋势(37%对50.5%,P=0.11),无进展生存期有缩短趋势(7.4对9.7个月;HR 1.25;P=0.14),总生存期无显著差异(19.1对20.1个月;HR 1.05;P=0.73)。
- 早期肿瘤退缩在BRAF突变患者中识别出9/17例敏感亚组,在RAS突变患者中识别出18/48例敏感亚组,并与显著更长的总生存期相关。
- 在RAS突变和BRAF突变患者中,两治疗组的缓解深度相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab in patients with RAS-mutant tumours needs to be further evaluated. Whether to treat patients with BRAF-mutant tumours with either bevacizumab or anti-epidermal growth factor receptor (EGFR) antibodies remains unclear. METHODS: Patients treated within the FIRE-3 trial were retrospectively tested for BRAF and RAS mutations using formalin fixated paraffin embedded (FFPE) tumour material applying pyrosequencing for KRAS and NRAS exon 2, 3 and 4 mutations as far as for BRAF mutations. Survival analysis was done using Kaplan-Meier estimation and differences were expressed using the log-rank test. Overall response rate (ORR) was compared using Fisher's exact test. Data from a central independent radiological response evaluation were used to calculate early tumour shrinkage (ETS) and depth of response (DpR). RESULTS: Overall, 188 patients with RAS-mutant tumours and 48 with BRAF-mutant tumours were identified. In BRAF-mutant patients, ORR was numerically higher in the cetuximab versus the bevacizumab arm (52% versus 40%), while comparable results were achieved for progression-free survival (PFS; hazard ratio [HR] = 0.84, p = 0.56) and overall survival (OS; HR 0.79, p = 0.45). RAS mutation was associated with a trend towards lower ORR (37% versus 50.5%, p = 0.11) and shorter PFS (7.4 versus 9.7 months; HR 1.25; p = 0.14) in patients receiving FOLFIRI plus cetuximab versus bevacizumab, but OS was comparable (19.1 versus 20.1 months; HR 1.05; p = 0.73), respectively. ETS identified subgroups sensitive to cetuximab-based treatment in both BRAF- (9/17) and RAS-mutant (18/48) patients and was associated with significantly longer OS. DpR was comparable between both treatment arms in RAS- and BRAF-mutant patients, respectively. CONCLUSIONS: In BRAF- and RAS-mutant patients, cetuximab- and bevacizumab-based treatment had comparable survival times. ETS represents an early parameter associated with the benefit from anti-EGFR, while this was not the case with vascular endothelial growth factor A blockade.
引用
- Stintzing S, Miller-Phillips L, Modest DP, et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer. 2017. PMID: 28463756. doi:10.1016/j.ejca.2017.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。